Edgewise Therapeutics shares surge 28% in pre-market trading

Previously, the company announced that it had reached an agreement with French pharmaceutical company Servier to sell its muscular atrophy business, with the total transaction value reaching up to $2.65 billion. This deal is expected to bring considerable cash returns to Edgewise and enable it to focus more on advancing other research and development pipelines. The market responded positively to this news.